Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model (2022)
- Authors:
- USP affiliated authors: PEREIRA, MAURÍCIO DOS SANTOS - FMRP ; MARANGONI, GLAUCE CRIVELARO DO NASCIMENTO - FORP ; BORTOLANZA, MARIZA - FMRP ; GUIMARAES, ELAINE APARECIDA DEL BEL BELLUZ - FORP
- Unidades: FMRP; FORP
- DOI: 10.3389/fphar.2022.1045465
- Subjects: NEUROLOGIA; INFLAMAÇÃO; CITOCINAS
- Keywords: Neuroinflammation; Cytokines; Tetracyclines; Parkinson’s disease; IL-1β; TNF-α; PGE2; COX-2
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Pharmacology
- ISSN: 1663-9812
- Volume/Número/Paginação/Ano: v. 13, on-line, 2022
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
PEREIRA, Maurício dos Santos et al. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Frontiers in Pharmacology, v. 13, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.1045465. Acesso em: 31 mar. 2026. -
APA
Pereira, M. dos S., Nascimento, G. C. do, Bortolanza, M., Michel, P. P., Raisman-Vozari, R., & Del Bel, E. A. (2022). Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Frontiers in Pharmacology, 13. doi:10.3389/fphar.2022.1045465 -
NLM
Pereira M dos S, Nascimento GC do, Bortolanza M, Michel PP, Raisman-Vozari R, Del Bel EA. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model [Internet]. Frontiers in Pharmacology. 2022 ; 13[citado 2026 mar. 31 ] Available from: https://doi.org/10.3389/fphar.2022.1045465 -
Vancouver
Pereira M dos S, Nascimento GC do, Bortolanza M, Michel PP, Raisman-Vozari R, Del Bel EA. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model [Internet]. Frontiers in Pharmacology. 2022 ; 13[citado 2026 mar. 31 ] Available from: https://doi.org/10.3389/fphar.2022.1045465 - Doxycycline and its derivative, COL‐3, decrease dyskinesia induced by L-DOPA in hemiparkinsonian rats
- Management with antibiotics in Parkinson's disease
- Interferon-γ involvement in the neuroinflammation associated with Parkinson’s disease and L-DOPA-induced dyskinesia
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of Parkinson's disease
- CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease
- The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress
- Rifampicin and its derivative Rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by α-Synuclein fibrillary aggregates
- Nociceptive response to L-DOPA-induced dyskinesia in hemiparkinsonian rats
- Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003268821.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
